Personalized and highly-targeted therapeutics are becoming more common, making local or regional production increasingly valuable for faster patient access. This underscores how a hybrid network combining large, centralized plants coupled with flexible regional sites will define the next era of resilient biomanufacturing.
The post Moving Beyond the Mega-Factory: Why the Future of Biomanufacturing is Agile, Distributed, and Resilient appeared first on MedCity News.
